Sorafenib Tosylate and Temsirolimus in Treating Patients With Recurrent Glioblastoma
Study Information
Alliance Study ID: N0572
NCT Study ID (ClinicalTrials.gov): NCT00329719
Alliance Committee: Neuro-Oncology
Disease or Cancer Type: Brain / Central Nervous System Cancer
Alliance Study Chair: Kurt Jaeckle
Status: COMPLETED
Study Description
This phase I/II trial studies the side effects and best dose of temsirolimus when given together with sorafenib tosylate and to see how well they work in treating patients with glioblastoma that has come back. Sorafenib tosylate may stop the growth of tumor cells by blocking blood flow to the tumor. Drugs used in chemotherapy, such as temsirolimus, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Sorafenib tosylate and temsirolimus may also stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving sorafenib tosylate with temsirolimus may kill more tumor cells.
Related Publications
For publications related to this and other clinical trials, visit the Alliance Publications Application.
Data Sources & Contacts
Full trial details
For more Information